Xu Yang, Liu Yang, Han Huimin, He Zhen, Cao Wei
Department of Oncology, Wuhan Third Hospital, Tongren Hospital of Wuhan University, Wuhan, Hubei, China.
Front Immunol. 2025 Jul 21;16:1633034. doi: 10.3389/fimmu.2025.1633034. eCollection 2025.
OBJECTIVE: This study was conducted to determine the prognostic relevance of neutrophil/eosinophil ratio (NER) in cancer patients receiving immune checkpoint inhibition therapy. METHODS: A comprehensive search of the literature was carried out across PubMed, EMBASE, and the Cochrane Library to identify relevant studies published before May 2025. Key clinical endpoints included overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and disease control rate (DCR). Additionally, a retrospective cohort analysis involving 67 hepatocellular carcinoma (HCC) patients who received ICIs at our center was undertaken to evaluate the prognostic significance of NER with respect to OS and PFS. RESULTS: This meta-analysis incorporated 12 studies comprising a total of 1,716 patients. Higher baseline NER was consistently associated with poorer clinical outcomes, including shorter OS (HR = 1.82, 95% CI: 1.57-2.11, < 0.001) and PFS (HR = 1.62, 95% CI: 1.34-2.97, < 0.001), as well as lower ORR (HR = 0.50, 95% CI: 0.37-0.68, < 0.001) and DCR (OR = 0.44, 95% CI: 0.31-0.61, < 0.001). Complementing these findings, analysis of a retrospective cohort from our institution involving HCC patients revealed that individuals with higher NER experienced significantly worse OS ( = 0.006) and PFS ( = 0.033) when compared to those with lower NER levels. CONCLUSION: These findings underscore the prognostic significance of pretreatment NER in cancer patients receiving ICI therapy. Integrating NER into standard clinical evaluation may enhance risk stratification and contribute to the personalization of treatment strategies.
目的：本研究旨在确定接受免疫检查点抑制治疗的癌症患者中中性粒细胞/嗜酸性粒细胞比值（NER）与预后的相关性。 方法：在PubMed、EMBASE和Cochrane图书馆全面检索文献，以识别2025年5月之前发表的相关研究。主要临床终点包括总生存期（OS）、无进展生存期（PFS）、客观缓解率（ORR）和疾病控制率（DCR）。此外，对我院67例接受免疫检查点抑制剂（ICI）治疗的肝细胞癌（HCC）患者进行回顾性队列分析，以评估NER对OS和PFS的预后意义。 结果：该荟萃分析纳入了12项研究，共1716例患者。较高的基线NER始终与较差的临床结局相关，包括较短的OS（HR = 1.82，95% CI：1.57 - 2.11，P < 0.001）和PFS（HR = 1.62，95% CI：1.34 - 2.97，P < 0.001），以及较低的ORR（HR = 0.50，95% CI：0.37 - 0.68，P < 0.001）和DCR（OR = 0.44，95% CI：0.31 - 0.61，P < 0.001）。补充这些发现的是，对我院涉及HCC患者的回顾性队列分析显示，与NER水平较低的患者相比，NER较高的患者OS（P = 0.006）和PFS（P = 0.033）明显更差。 结论：这些发现强调了治疗前NER在接受ICI治疗的癌症患者中的预后意义。将NER纳入标准临床评估可能会加强风险分层，并有助于治疗策略的个性化。
Zotero 插件
